HUTCHMED (China) Ltd (HCM): Shareholders' Equity
$1.25B
As of 2025-12-31
+25.2%
3-year compound annual growth
+19.2%
5-year compound annual growth
+28.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.25B | +62.1% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $771.85M | +3.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $743.39M | +16.7% | 2026-03-05, Balance as of period end |
| 2022-12-31 | $636.87M | -38.7% | 2025-03-19, Balance as of period end |
| 2021-12-31 | $1.04B | +100.3% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $518.95M | +65.8% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $312.90M | -24.1% | 2022-03-03, Balance as of period end |
| 2018-12-31 | $412.25M | -15.0% | 2021-03-04, Balance as of period end |
| 2017-12-31 | $484.97M | +137.7% | 2020-03-03, Balance as of period end |
| 2016-12-31 | $204.06M | +99.5% | 2019-03-11, Balance as of period end |
| 2015-12-31 | $102.28M | +79.7% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $56.91M | n/a | 2017-03-13, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $314.69M | +39.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$2.09B | n/m |
| Insmed Inc (INSM) | 2025-12-31 | $738.98M | +158.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $114.83M | +94.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $648.02M | +191.4% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗